<SEC-DOCUMENT>0001193125-18-317884.txt : 20181105
<SEC-HEADER>0001193125-18-317884.hdr.sgml : 20181105
<ACCEPTANCE-DATETIME>20181105091558
ACCESSION NUMBER:		0001193125-18-317884
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20181105
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181105
DATE AS OF CHANGE:		20181105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RESMED INC
		CENTRAL INDEX KEY:			0000943819
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				980152841
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15317
		FILM NUMBER:		181158962

	BUSINESS ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
		BUSINESS PHONE:		8587462400

	MAIL ADDRESS:	
		STREET 1:		9001 SPECTRUM CENTER BLVD.
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92123
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d647737d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>November&nbsp;5, 2018 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ResMed Inc.
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-15317</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">98-0152841</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9001 Spectrum Center Boulevard </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San Diego, California 92123 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(858) <FONT STYLE="white-space:nowrap">836-5000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former Name or
Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT
STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Emerging growth
company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;7.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulation FD Disclosure. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;5, 2018, ResMed Inc. (&#147;<U>ResMed</U>&#148;) issued a press release, a copy of which is attached hereto as Exhibit 99.1, announcing its
entry into an Agreement and Plan of Merger (the &#147;<U>Merger Agreement</U>&#148;) with ResMed Operations Inc., (&#147;<U>ResMed Operations</U>&#148;), a Delaware corporation and wholly owned subsidiary of ResMed, Evolved Sub, Inc. a Delaware
corporation and a wholly owned subsidiary of ResMed Operations (&#147;<U>Merger Sub</U>&#148;), MatrixCare Holdings, Inc., a Delaware corporation (&#147;<U>MatrixCare</U>&#148;), and OPE LGI Holdings Limited, a Canadian private company, in its
capacity as the agent acting on behalf of the holders of common stock of MatrixCare, providing for the merger of Merger Sub with and into MatrixCare, such that MatrixCare will become the surviving company and a wholly owned subsidiary of ResMed
Operations (the &#147;<U>Merger</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in this Item 7.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> (including
Exhibit 99.1 attached hereto) is being furnished and shall not be deemed to be &#147;filed&#148; for the purpose of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;<U>Exchange Act</U>&#148;), or otherwise subject to the
liability of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information relating solely to the Merger Agreement and the proposed Merger set forth above in Item 7.01 is incorporated herein by reference, except for
Exhibit 99.1, which shall not be deemed &#147;filed&#148; and is not incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) <U>Exhibits</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d647737dex991.htm">Press Release dated November&nbsp;5, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934, as
amended. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>RESMED INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;5, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Pendarvis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: David Pendarvis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Its: Chief administrative officer, global general counsel and secretary</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d647737dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g647737g1104024719948.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g647737g1104024720167.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>For media:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>For investors:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jayme Rubenstein</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amy Wakeham</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">+1 858.836.6798</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">+1 858.836.5000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>news@resmed.com</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>investorrelations@resmed.com</U></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ResMed to Acquire MatrixCare, Expands
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Out-of-Hospital</FONT></FONT> SaaS Portfolio into Long-Term Care Settings </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Expands ResMed&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> software portfolio into skilled nursing and senior living verticals</I> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Enhances ResMed&#146;s ability to improve patient transitions of care and provider efficiencies</I>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Purchase price $750</I><I></I><I>&nbsp;million, accretive to <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
gross margin and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> diluted earnings per share</I> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SAN DIEGO &#150;
November</B><B></B><B>&nbsp;5, 2018 &#150; </B>ResMed (NYSE: RMD, ASX: RMD) today announced it has signed a definitive agreement to acquire privately held MatrixCare, a leader in U.S. long-term post-acute care software, serving more than 15,000
providers across skilled nursing, life plan communities, senior living and private duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These care settings are complementary to ResMed&#146;s current <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">software-as-a-service</FONT></FONT></FONT> (SaaS) offerings in home medical equipment, home health and hospice, delivered through Brightree and
HEALTHCARE<I>first</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Named &#147;Best in KLAS&#148; for long-term post-acute care software in 2017 and 2018, Minnesota-based MatrixCare&#146;s
electronic health record (EHR) solution supports a wide range of long-term care settings, enabling providers to increase patient management efficiencies and deliver superior clinical care. Its wide range of offerings includes point of care, lead and
referral management, claims processing, payroll and nutrition management, among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The acquisition of MatrixCare is an excellent addition to
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> software portfolio that we can offer our healthcare provider customers,&#148; said ResMed CEO Mick Farrell. &#147;ResMed is the world&#146;s leading
tech-driven medical device company and is well positioned to be the leading <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> software provider in the market. With our portfolio including Brightree,
HEALTHCARE<I>first</I>, and MatrixCare, we will streamline transitions of care, creating better outcomes for patients, caregivers, and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-hospital</FONT></FONT> healthcare
providers.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;By establishing a technology footprint across these major care settings, ResMed will drive an integrated ecosystem of solutions,
such as maintaining single-patient records across multiple care settings, generating analytics and insights that can be applied to individuals and whole populations, and streamlining processes for healthcare providers across the care
continuum,&#148; said ResMed SaaS President Raj Sodhi. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We&#146;re thrilled to be part of a global healthcare leader that shares our mission,
leveraging technology to improve the quality of life for seniors and those who care for them,&#148; said MatrixCare CEO John Damgaard. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;Out-of-hospital</FONT></FONT> care today
is incredibly fragmented, with those struggling to navigate across care settings, and providers often unable to assist. Like MatrixCare, ResMed&#146;s software solutions smooth the path to faster, better care, and a smarter way for clinicians to do
business. The entire MatrixCare team and I look forward to joining forces with them.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of the transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement terms, ResMed will acquire MatrixCare for $750&nbsp;million, which ResMed will fund primarily with its credit facility. In calendar year
2018, MatrixCare pro forma net revenue is estimated to be approximately $122&nbsp;million, with a pro forma EBITDA of approximately $30&nbsp;million. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction is expected to be immediately accretive to <FONT STYLE="white-space:nowrap">non-GAAP</FONT>
gross margin and <FONT STYLE="white-space:nowrap">non-GAAP</FONT> diluted earnings per share after close and beyond. The purchase price of&nbsp;$750&nbsp;million represents a valuation multiple of 25 times the expected calendar year 2018 pro forma
EBITDA of $30&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transaction is expected to close by the end of the second quarter of ResMed&#146;s fiscal year 2019, subject to customary
closing conditions and any applicable regulatory approvals. Following completion of the transaction, ResMed intends to suspend its share repurchase program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On completion of the transaction, MatrixCare will continue to operate as a standalone business within ResMed&#146;s SaaS portfolio, with targeted commercial,
technical and operating links to ResMed and Brightree. There will be no immediate changes to management, locations or business processes.&nbsp;MatrixCare CEO John Damgaard will continue in his current role, reporting to Raj Sodhi. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ResMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ResMed (NYSE: RMD, ASX: RMD), a
world-leading connected health company with more than 6&nbsp;million cloud-connected devices for daily remote patient monitoring, changes lives with every breath. Its award-winning devices and software solutions help treat and manage sleep apnea,
chronic obstructive pulmonary disease and other respiratory conditions. Its <FONT STYLE="white-space:nowrap">6,000-member</FONT> team strives to improve patients&#146; quality of life, reduce the impact of chronic disease and save healthcare costs
in more than 120 countries. <U>ResMed.com</U> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MatrixCare </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current and multi-time winner of the prestigious Best in KLAS for Long-Term Care Software award, MatrixCare is the complete solution for growing organizations
that need to successfully manage risk in care delivery across the long-term post-acute care (LTPAC) spectrum. Trusted by more than 13,000 facility-based care settings and more than 2,500 home care, home health and hospice organizations,
MatrixCare&#146;s solutions help Accountable Care Organizations, skilled nursing and senior living providers, life plan communities, and home health organizations to connect, collaborate and prosper as we migrate to a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fee-for-value</FONT></FONT> healthcare system. In addition to electronic health record components purpose-built for any LTPAC care-setting, MatrixCare also includes solutions to
systematically increase clinical quality: Enterprise Analytics, robust Clinical Decision Support and the industry&#146;s first Care Coordination platform to create a true, person-centric, <FONT STYLE="white-space:nowrap">e-longitudinal</FONT> health
record and enable LTPAC providers to efficiently manage the populations under their care. Visit <U>www.matrixcare.com</U> and <U>www.carecommunity.com</U> for more information. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-looking statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements contained in this
news release that are not historical facts are &#147;forward-looking&#148; statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements &#150; including statements regarding ResMed&#146;s
projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products and the integration of acquisitions &#150; are subject to risks and uncertainties that could cause actual results to
materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed&#146;s periodic reports on file with the U.S. Securities&nbsp;&amp; Exchange Commission. ResMed does not
undertake to update its forward-looking statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g647737g1104024719948.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g647737g1104024719948.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !( &P# 2(  A$! Q$!_\0
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MJO\ :'V,>;OW[=QV;LYSCI70UV5ZU-Q4*-TNIY^%P]6,W/$--]'V"BBBN,]
M**** ,W7;"34=)FAAO)[.7AA/;_ZP ') ^N,5+I%\NI:5;W:Q3Q"1?N7";7&
M..1^%7:YN.0Z)XH:VVW]VNJN93(QS%;;1T]A_P#6IWTL:17-%HZ2BBBD9A11
M10 45S/CC5K_ $OP^TVE\S>:J2.HW&-3GG'Y#\:Y/0O%OBV;3R4T]K]0Y F9
M<'H./>LI58QERL[Z.75:U'VT6K7MJ['J5%%%:G %%%% !1110 52U;3EU;2K
MBP>:2%9UVF2,X9?I5VB@:;3NCE-,U2;2-4;09[2<:=86H;^T9VX; ')/XD?A
M71VE_:7UJMU:W$<L#'"R*W!HO[&WU.PGLKI-\$R%'7/45RNK^ DGT&TTO1[R
M2QB@E:0Y8G>3U)QWI.Z.A>RJM<SY7]Z]3KI)X8G5))41G.%5F )^E<Q>>.=.
MC\0-H(\U;AF\@3@?*DA''ZD56UWP&^LWVFW!U25/LL*1.2,EMO\ $/0FMY_#
M.D2:RNK/9H;Q2#YGN.AQZU+YGL:06%@KS;E=/;2SZ'&^#_"GB#3?$CW.I2YM
M@K+)F3<)B>G'UYKT9$2-=J(JJ.RC IU%.$%!61GBL5/$SYY_@8VO^*M(\,BW
M.JW/D^>6\L!"V<8ST^HK%'Q4\(D@?VD1GUB;_"O.OBY?I?>.;>Q>39!:0HDC
M?W2YW,?^^=M7/%VM_#^?PS<6VC6D3W[@+"\4#(4.1\Q) [?G3N<Y[)8WUKJ5
MG'=V<Z3V\@RDB'(-6*\)T+Q5?>!/!4=N+?=?ZE<-/:Q39 CBP%WD?[3 X'?K
M6G>>,/&7AV"#4KZ_TB_@9PLMK"X+IGMQ_/FBXK'L=%>7>-OB3>6$>DQ:*D<?
M]H6R7/VB<9"*QP!^'<]JDT;5_'L6JVBR?V?K>GSMAYK21<1CN=W;KW'-.X'8
M:]XPT3PU/##JEV89)E+HH0MD XSQ5K0_$&F^([)[O3)S-"DAC9BI7#  ]_J*
M\;\<Y\3?%5].1B8[:+RCCL$1I&_7BF>&?%!\._"G5&A?;>75Z8;?'4$QKN;\
M!^N*5QV/2[CXG>%+:XE@DU$[XG*-MB8C(.#@@<UUJ.)(U=<X8 C(QUKYFLM
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KP/O]QC'ITHHI@:OP=TRZ-]K6LWT,L<TK",&1"NXL2[D9]]M>M444T)G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g647737g1104024720167.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g647737g1104024720167.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  U /\# 2(  A$! Q$!_\0
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MI-^VJ)^1%5+V4&O,^AK#X9>$OL]K<?V8?-V(^?M$G7 /]ZO%_'W_ "/6K_\
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@6A:VT=G;K!$7**21O<N>3GJ23WHHH<I/1L:BEJD?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
